CytoMed Therapeutics (GDTC) Total Liabilities (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Total Liabilities for 5 consecutive years, with $872875.3 as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 13.39% to $872875.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $872875.3 through Dec 2025, up 13.39% year-over-year, with the annual reading at $879762.0 for FY2025, 17.38% up from the prior year.
  • Total Liabilities hit $872875.3 in Q4 2025 for CytoMed Therapeutics, up from $769789.0 in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $3.3 million in Q4 2022 to a low of $769789.0 in Q4 2024.
  • Historically, Total Liabilities has averaged $1.7 million across 5 years, with a median of $872875.3 in 2025.
  • Biggest five-year swings in Total Liabilities: increased 29.99% in 2022 and later plummeted 75.09% in 2023.
  • Year by year, Total Liabilities stood at $2.6 million in 2021, then grew by 29.99% to $3.3 million in 2022, then plummeted by 75.09% to $833067.9 in 2023, then dropped by 7.6% to $769789.0 in 2024, then increased by 13.39% to $872875.3 in 2025.
  • Business Quant data shows Total Liabilities for GDTC at $872875.3 in Q4 2025, $769789.0 in Q4 2024, and $833067.9 in Q4 2023.